CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
Although cryoactivation combined with pembrolizumab was safe and well tolerated in patients with NSCLC, therapeutic benefits were not evident compared with historical cohorts of ICI monotherapy. Correlative analyses validated CD8<sup>+</sup> T cell recruitment in patients deriving CB.
Authors
- Jean Chalaoui
- Moïshe Liberman (ORCID: https://orcid.org/0000-0002-9964-1232)
- Adéline Jouquan
- Normand Blais (ORCID: https://orcid.org/0000-0003-2698-4362)
- Marie Florescu (ORCID: https://orcid.org/0000-0002-3811-4148)
- Samer Tabchi (ORCID: https://orcid.org/0000-0001-9225-9412)
- Vincent Quoc‐Huy Trinh
- Bertrand Routy (ORCID: https://orcid.org/0000-0002-0756-6571)
- Antoine Desîlets (ORCID: https://orcid.org/0000-0002-9382-7597)
- Wiam Belkaïd
- Arielle Elkrief (ORCID: https://orcid.org/0000-0003-1981-1535)
- Eleyine Zarour
- Gil Pinheiro (ORCID: https://orcid.org/0000-0002-1954-3545)
- Olivier Salko
- Mustapha Tehfé (ORCID: https://orcid.org/0000-0002-1380-5110)
- A. A. Thibaudeau
- Marc‐Antoine Nolin (ORCID: https://orcid.org/0000-0003-1992-5145)
- J. C. A. Stagg
- Philippe Stephenson
- Julie Malo (ORCID: https://orcid.org/0009-0005-3613-2210)
Institutions
- Centre Technologique des Résidus Industriels (CA)
- Institute for Research in Immunology and Cancer (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100737
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13